title: Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.
abstract: BACKGROUND
  Infusion of anti-tumour necrosis factor-alpha appears to be highly effective in patients with Crohn's disease.
  
  
  OBJECTIVE
  To assess the effect of infliximab on the quality of life in patients with active or fistulizing disease, as measured by the inflammatory bowel disease questionnaire, and to examine the impact on its four dimensions.
  
  
  METHODS
  An observational study was conducted in 65 patients. An infusion of 5 mg/kg infliximab was given at week 0 in patients with active disease and at week 0, 2 and 6 in fistulizing disease. Changes from baseline in the total and dimensional inflammatory bowel disease questionnaire scores were calculated and compared between the patient groups. Potential predictors of change in the quality of life were identified.
  
  
  RESULTS
  In the active disease group, at week 4, the mean total and dimensional inflammatory bowel disease questionnaire scores improved compared to baseline (P < 0.001). In the fistulizing group, at week 6, all scores changed from baseline (P < 0.05). Improvement in the total inflammatory bowel disease questionnaire score correlated well with the improvement of the Crohn's disease activity index. Systemic and social scores improved more than bowel and emotional scores. Inflammatory Crohn's disease and a young age at diagnosis were predictors for a better response to infliximab therapy.
  
  
  CONCLUSIONS
  Infliximab therapy improves all dimensions of the quality of life in patients with Crohn's disease.
authors.affiliation: Department of Gastroenterology, University Hospital Maastricht, NL-6202 AZ Maastricht, The Netherlands.
authors.forename: B P J
authors.initials: BP
authors.lastname: van Balkom
authors.forename: E J
authors.initials: EJ
authors.lastname: Schoon
authors.forename: R W
authors.initials: RW
authors.lastname: Stockbrügger
authors.forename: F L
authors.initials: FL
authors.lastname: Wolters
authors.forename: R A
authors.initials: RA
authors.lastname: van Hogezand
authors.forename: S J H
authors.initials: SJ
authors.lastname: van Deventer
authors.forename: B
authors.initials: B
authors.lastname: Oldenburg
authors.forename: H M
authors.initials: HM
authors.lastname: van Dullemen
authors.forename: M G V M
authors.initials: MG
authors.lastname: Russel
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D011788:Quality of Life; D012720:Severity of Illness Index; D012919:Social Behavior; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab